$2.07
0.48% yesterday
NYSE, Sep 03, 10:00 pm CET
ISIN
IE000LK2BOB4
Symbol
MURA

Mural Oncology Stock price

$2.07
+0.22 11.89% 1M
-1.36 39.65% 6M
-1.15 35.71% YTD
-1.09 34.49% 1Y
-1.73 45.53% 3Y
-1.73 45.53% 5Y
-1.73 45.53% 10Y
-1.73 45.53% 20Y
NYSE, Closing price Wed, Sep 03 2025
-0.01 0.48%
ISIN
IE000LK2BOB4
Symbol
MURA
Industry

Key metrics

Basic
Market capitalization
$36.0m
Enterprise Value
$-41.1m
Net debt
positive
Cash
$77.1m
Shares outstanding
17.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
0.3
P/B
0.6
Financial Health
Equity Ratio
82.9%
Return on Equity
-91.5%
ROCE
-229.4%
ROIC
-1,866.5%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-131.9m | $-60.7m
EBIT
$-135.7m | $-109.1m
Net Income
$-147.2m | $-107.6m
Free Cash Flow
$-130.1m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
22.4% | 54.9%
EBIT
21.6% | 21.1%
Net Income
15.1% | 16.3%
Free Cash Flow
19.9%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-8.5
FCF per Share
$-7.5
Short interest
1.2%
Employees
104
Rev per Employee
$0.0
Show more

Is Mural Oncology a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Mural Oncology Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Mural Oncology forecast:

6x Buy
67%
3x Hold
33%

Analyst Opinions

9 Analysts have issued a Mural Oncology forecast:

Buy
67%
Hold
33%

Financial data from Mural Oncology

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 29 29
20% 20%
-
- Research and Development Expense 107 107
22% 22%
-
-132 -132
22% 22%
-
- Depreciation and Amortization 3.76 3.76
20% 20%
-
EBIT (Operating Income) EBIT -136 -136
22% 22%
-
Net Profit -147 -147
15% 15%
-

In millions USD.

Don't miss a Thing! We will send you all news about Mural Oncology directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Mural Oncology Stock News

Neutral
Business Wire
14 days ago
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Mural Oncology plc (NASDAQ: MURA) to XOMA Royalty Corporation for $2.035 per share and, up to an additional $0.205 per share under certain conditions, is fair to Mural shareholders. Halper Sadeh encourages Mural shareholders to click here to learn more about their legal rights and opti...
Neutral
GlobeNewsWire
15 days ago
WALTHAM, Mass., DUBLIN, Ireland and EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company (“Mural”), and XOMA Royalty Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator (“XOMA Royalty”), announced today they have entered into a definitive agreement pursuant to which XRA 5 Corp., a newly formed company wholly...
Neutral
The Motley Fool
about one month ago
Mural Oncology (MURA) Q2 Loss Widens 49%
More Mural Oncology News

Company Profile

Mural Oncology Plc operates as a clinical stage company. It focus on discovering and developing immuno therapies that may meaningfully improve the lives of patients with cancer. Its portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. The company was founded in May 2017 and is headquartered in Dublin, Ireland.

Head office Ireland
CEO Caroline Loew
Employees 104
Founded 2017
Website www.muraloncology.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today